Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2011 16:05 ET | Source: Aastrom Biosciences, Inc.

Webcast Alert: Aastrom to Host Third Quarter 2011 Investor Call on Tuesday, November 8, 2011

ANN ARBOR, Mich., Oct. 31, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
October 13, 2011 16:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Appoints Brian Gibson as Vice President, Finance

ANN ARBOR, Mich., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
October 03, 2011 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Granted European Composition-of-Matter Patent for Ixmyelocel-T

ANN ARBOR, Mich., Oct. 3, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
September 23, 2011 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Present at the Sixth Annual JMP Securities Healthcare Conference

ANN ARBOR, Mich., Sept. 23, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
September 19, 2011 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Announces Positive 12-Month Safety and Efficacy Data From IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy

Results presented today at 15th Annual Heart Failure Society of America Scientific Meeting Aastrom also announces results of six-month interim analysis of DCM patients treated with ixmyelocel-T...
September 16, 2011 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Chief Scientific Officer Ronnda Bartel, PhD, to Present at the Cell Therapy Commercialization Summit

ANN ARBOR, Mich., Sept. 16, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
September 14, 2011 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Present 12-Month Data From the IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy

ANN ARBOR, Mich., Sept. 14, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
September 08, 2011 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Present at the 13th Annual Rodman & Renshaw Healthcare Conference

ANN ARBOR, Mich., Sept. 8, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
September 01, 2011 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Present at the Stifel Nicolaus Healthcare Conference

ANN ARBOR, Mich., Sept. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
August 15, 2011 16:01 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Operating Results for the Quarter and Six Months Ended June 30, 2011

Phase 3 REVIVE-CLI clinical trial to begin next quarter Final Phase 2b CLI data presentation at AHA meeting in November Final Phase 2 DCM data presentation at HFSA meeting next month...